Renaissance Technologies’s Fennec Pharmaceuticals FENC Stock Holding History

Renaissance Technologies’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.44M	Buy	+134,200	New	+$1.1M	﹤0.01%	2144
2026 Q1	–	Sell	-20,000	Closed	-$154K	–	3384
2025 Q4	$154K	Buy	20,000 +9,400	+89%	+$77.2K	﹤0.01%	2932
2025 Q3	$99.2K	Buy	+10,600	New	+$91.8K	﹤0.01%	3251
2024 Q2	–	Sell	-139,900	Closed	-$1.56M	–	3639
2024 Q1	$1.56M	Buy	+139,900	New	+$1.4M	﹤0.01%	2195
2021 Q3	–	Sell	-20,284	Closed	-$148K	–	3575
2021 Q2	$148K	Buy	+20,284	New	+$135K	﹤0.01%	3307
2020 Q3	–	Sell	-134,000	Closed	-$1.12M	–	3461
2020 Q2	$1.12M	Buy	134,000 +57,904	+76%	+$431K	﹤0.01%	2489
2020 Q1	$452K	Buy	76,096 +52,296	+220%	+$341K	﹤0.01%	2805
2019 Q4	$154K	Buy	+23,800	New	+$128K	﹤0.01%	3245
2019 Q2	–	Sell	-31,100	Closed	-$151K	–	3609
2019 Q1	$151K	Buy	+31,100	New	+$204K	﹤0.01%	3247
2018 Q2	–	Sell	-34,800	Closed	-$421K	–	3348
2018 Q1	$421K	Buy	+34,800	New	+$329K	﹤0.01%	2968

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCA

Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Renaissance Technologies's FENC Position: Q2 2026 in Review

Renaissance Technologies opened a new position in Fennec Pharmaceuticals (FENC) in Q2 2026: 134,200 shares worth $1.44M. The stake represents ﹤0.01% of the portfolio and ranks #2144 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in FENC as recently as Q4 2025.

Renaissance Technologies first reported a position in FENC in Q1 2018 and has held it in 10 quarters since. The position peaked at $1.56M in Q1 2024. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

Renaissance Technologies held 134,200 shares of Fennec Pharmaceuticals worth $1.44M as of Q2 2026.
Fennec Pharmaceuticals was a new Renaissance Technologies position in Q2 2026.
Fennec Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2144 holding.
Renaissance Technologies first reported a position in Fennec Pharmaceuticals in Q1 2018 and has held it in 10 quarters since.
Renaissance Technologies's Fennec Pharmaceuticals position peaked at $1.56M in Q1 2024.
105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.